Compare CTM & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTM | GANX |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.7M | 78.2M |
| IPO Year | 2022 | 2021 |
| Metric | CTM | GANX |
|---|---|---|
| Price | $0.72 | $2.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.00 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 1.2M | 548.9K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.33 | 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $52,866,001.00 | $55,180.00 |
| Revenue This Year | $20.36 | N/A |
| Revenue Next Year | $6.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.10 | N/A |
| 52 Week Low | $0.48 | $1.41 |
| 52 Week High | $1.56 | $4.34 |
| Indicator | CTM | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 50.15 | 53.96 |
| Support Level | $0.48 | $1.55 |
| Resistance Level | $1.21 | $2.40 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 86.77 | 84.46 |
Castellum Inc is engaged in providing information technology services. The company provides financial services, healthcare, and other users of large data applications with services that include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and MBSE. In addition to constantly innovating and enhancing organic capabilities, Castellum is acquiring technology companies in the areas of cybersecurity, information technology, electronic warfare, information warfare, and information operations with businesses in the defense, federal, civilian, and commercial markets.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.